Incyte报告血液疾病研究结果

2025-06-17 01:23

Incyte (NASDAQ:INCY) reported early results from two studies on INCA033989, a new targeted antibody aimed at patients with blood disorders linked to mutant calreticulin.
In these studies, 86% of high-risk patients with essential thrombocythemia who carried a CALR mutation and received 400 mg or more of INCA033989 had either a complete or partial improvement in their blood cell levels, with 82% reaching full recovery.
Additionally, a significant decrease in the mutant calreticulin variant allele frequency in peripheral blood was noted in 89% of patients evaluated, which correlated with the observed hematologic responses.
The safety profile of INCA033989 also showed promise, with no dose-limiting toxicities reported, and 98% of patients continued their treatment without reaching the maximum tolerated dose, the company added.
The stock is up 4.5%.

More on Incyte